BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Davies JC, Cunningham S, Harris WT, Lapey A, Regelmann WE, Sawicki GS, Southern KW, Robertson S, Green Y, Cooke J, Rosenfeld M; KIWI Study Group. Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study. Lancet Respir Med 2016;4:107-15. [PMID: 26803277 DOI: 10.1016/S2213-2600(15)00545-7] [Cited by in Crossref: 176] [Cited by in F6Publishing: 59] [Article Influence: 29.3] [Reference Citation Analysis]
Number Citing Articles
1 Maiuri L, Raia V, Kroemer G. Strategies for the etiological therapy of cystic fibrosis. Cell Death Differ 2017;24:1825-44. [PMID: 28937684 DOI: 10.1038/cdd.2017.126] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 7.2] [Reference Citation Analysis]
2 Connett GJ. Lumacaftor-ivacaftor in the treatment of cystic fibrosis: design, development and place in therapy. Drug Des Devel Ther 2019;13:2405-12. [PMID: 31409974 DOI: 10.2147/DDDT.S153719] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
3 Marangi M, Pistritto G. Innovative Therapeutic Strategies for Cystic Fibrosis: Moving Forward to CRISPR Technique. Front Pharmacol 2018;9:396. [PMID: 29731717 DOI: 10.3389/fphar.2018.00396] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
4 Clancy JP. Rapid therapeutic advances in CFTR modulator science. Pediatr Pulmonol 2018;53:S4-S11. [PMID: 30289627 DOI: 10.1002/ppul.24157] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 8.0] [Reference Citation Analysis]
5 Burgener EB, Moss RB. Cystic fibrosis transmembrane conductance regulator modulators: precision medicine in cystic fibrosis. Curr Opin Pediatr 2018;30:372-7. [PMID: 29538046 DOI: 10.1097/MOP.0000000000000627] [Cited by in Crossref: 29] [Cited by in F6Publishing: 17] [Article Influence: 7.3] [Reference Citation Analysis]
6 Rosenfeld M, Cunningham S, Harris WT, Lapey A, Regelmann WE, Sawicki GS, Southern KW, Chilvers M, Higgins M, Tian S, Cooke J, Davies JC; KLIMB study group. An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2-5 years (KLIMB). J Cyst Fibros 2019;18:838-43. [PMID: 31053538 DOI: 10.1016/j.jcf.2019.03.009] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 12.7] [Reference Citation Analysis]
7 Hubert D, Marguet C, Benichou J, DeSouza C, Payen-Champenois C, Kinnman N, Chandarana K, Munck A, Fajac I; BRIO Study Group. Real-World Long-Term Ivacaftor for Cystic Fibrosis in France: Clinical Effectiveness and Healthcare Resource Utilization. Pulm Ther 2021. [PMID: 34101145 DOI: 10.1007/s41030-021-00158-5] [Reference Citation Analysis]
8 Valamparampil JJ, Gupte GL. Cystic fibrosis associated liver disease in children. World J Hepatol 2021; 13(11): 1727-1742 [PMID: 34904041 DOI: 10.4254/wjh.v13.i11.1727] [Reference Citation Analysis]
9 Comegna M, Terlizzi V, Salvatore D, Colangelo C, Di Lullo AM, Zollo I, Taccetti G, Castaldo G, Amato F. Elexacaftor-Tezacaftor-Ivacaftor Therapy for Cystic Fibrosis Patients with The F508del/Unknown Genotype. Antibiotics (Basel) 2021;10:828. [PMID: 34356748 DOI: 10.3390/antibiotics10070828] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
10 Milla CE, Ratjen F, Marigowda G, Liu F, Waltz D, Rosenfeld M; VX13-809-011 Part B Investigator Group *. Lumacaftor/Ivacaftor in Patients Aged 6-11 Years with Cystic Fibrosis and Homozygous for F508del-CFTR. Am J Respir Crit Care Med 2017;195:912-20. [PMID: 27805836 DOI: 10.1164/rccm.201608-1754OC] [Cited by in Crossref: 93] [Cited by in F6Publishing: 29] [Article Influence: 18.6] [Reference Citation Analysis]
11 Naehrig S, Chao CM, Naehrlich L. Cystic Fibrosis. Dtsch Arztebl Int 2017;114:564-74. [PMID: 28855057 DOI: 10.3238/arztebl.2017.0564] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
12 Saint-Criq V, Gray MA. Role of CFTR in epithelial physiology. Cell Mol Life Sci 2017;74:93-115. [PMID: 27714410 DOI: 10.1007/s00018-016-2391-y] [Cited by in Crossref: 127] [Cited by in F6Publishing: 125] [Article Influence: 21.2] [Reference Citation Analysis]
13 Guimbellot J, Solomon GM, Baines A, Heltshe SL, VanDalfsen J, Joseloff E, Sagel SD, Rowe SM; GOALe(2) Investigators. Effectiveness of ivacaftor in cystic fibrosis patients with non-G551D gating mutations. J Cyst Fibros 2019;18:102-9. [PMID: 29685811 DOI: 10.1016/j.jcf.2018.04.004] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
14 Petrocheilou A, Kaditis AG, Loukou I. Pancreatitis in A Patient with Cystic Fibrosis Taking Ivacaftor. Children (Basel) 2020;7:E6. [PMID: 31940891 DOI: 10.3390/children7010006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Balfour-Lynn IM, King JA. CFTR modulator therapies - Effect on life expectancy in people with cystic fibrosis. Paediatr Respir Rev 2020:S1526-0542(20)30081-6. [PMID: 32565113 DOI: 10.1016/j.prrv.2020.05.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
16 Terlizzi V, Colangelo C, Marsicovetere G, D'Andria M, Francalanci M, Innocenti D, Masi E, Avarello A, Taccetti G, Amato F, Comegna M, Castaldo G, Salvatore D. Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor Therapy in Three Subjects with the Cystic Fibrosis Genotype Phe508del/Unknown and Advanced Lung Disease. Genes (Basel) 2021;12:1178. [PMID: 34440351 DOI: 10.3390/genes12081178] [Reference Citation Analysis]
17 Rosenfeld M, Wainwright CE, Higgins M, Wang LT, McKee C, Campbell D, Tian S, Schneider J, Cunningham S, Davies JC; ARRIVAL study group. Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study. Lancet Respir Med 2018;6:545-53. [PMID: 29886024 DOI: 10.1016/S2213-2600(18)30202-9] [Cited by in Crossref: 102] [Cited by in F6Publishing: 31] [Article Influence: 25.5] [Reference Citation Analysis]
18 Sepahzad A, Morris-Rosendahl DJ, Davies JC. Cystic Fibrosis Lung Disease Modifiers and Their Relevance in the New Era of Precision Medicine. Genes (Basel) 2021;12:562. [PMID: 33924524 DOI: 10.3390/genes12040562] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Muhlebach MS, Clancy JP, Heltshe SL, Ziady A, Kelley T, Accurso F, Pilewski J, Mayer-Hamblett N, Joseloff E, Sagel SD. Biomarkers for cystic fibrosis drug development. J Cyst Fibros 2016;15:714-23. [PMID: 28215711 DOI: 10.1016/j.jcf.2016.10.009] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 7.3] [Reference Citation Analysis]
20 McGarry ME, McColley SA. Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype. Pediatr Pulmonol 2021;56:1496-503. [PMID: 33470563 DOI: 10.1002/ppul.25285] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
21 Lahiri T, Sullivan JS. Recent advances in the early treatment of cystic fibrosis: Bridging the gap to highly effective modulator therapy. Pediatr Pulmonol 2021. [PMID: 34473419 DOI: 10.1002/ppul.25660] [Reference Citation Analysis]
22 Ghelani DP, Schneider-Futschik EK. Emerging Cystic Fibrosis Transmembrane Conductance Regulator Modulators as New Drugs for Cystic Fibrosis: A Portrait of in Vitro Pharmacology and Clinical Translation. ACS Pharmacol Transl Sci 2020;3:4-10. [PMID: 32259083 DOI: 10.1021/acsptsci.9b00060] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
23 Rowe SM, Daines C, Ringshausen FC, Kerem E, Wilson J, Tullis E, Nair N, Simard C, Han L, Ingenito EP, McKee C, Lekstrom-Himes J, Davies JC. Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis. N Engl J Med 2017;377:2024-35. [PMID: 29099333 DOI: 10.1056/NEJMoa1709847] [Cited by in Crossref: 244] [Cited by in F6Publishing: 100] [Article Influence: 48.8] [Reference Citation Analysis]
24 Mall MA, Mayer-Hamblett N, Rowe SM. Cystic Fibrosis: Emergence of Highly Effective Targeted Therapeutics and Potential Clinical Implications. Am J Respir Crit Care Med 2020;201:1193-208. [PMID: 31860331 DOI: 10.1164/rccm.201910-1943SO] [Cited by in Crossref: 34] [Cited by in F6Publishing: 17] [Article Influence: 17.0] [Reference Citation Analysis]
25 Davies JC, Wainwright CE, Sawicki GS, Higgins MN, Campbell D, Harris C, Panorchan P, Haseltine E, Tian S, Rosenfeld M. Ivacaftor in Infants Aged 4 to <12 Months with Cystic Fibrosis and a Gating Mutation. Results of a Two-Part Phase 3 Clinical Trial. Am J Respir Crit Care Med 2021;203:585-93. [PMID: 33023304 DOI: 10.1164/rccm.202008-3177OC] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 11.0] [Reference Citation Analysis]
26 Quon BS, Rowe SM. New and emerging targeted therapies for cystic fibrosis. BMJ 2016;352:i859. [PMID: 27030675 DOI: 10.1136/bmj.i859] [Cited by in Crossref: 87] [Cited by in F6Publishing: 66] [Article Influence: 14.5] [Reference Citation Analysis]
27 Bergeron C, Cantin AM. New Therapies to Correct the Cystic Fibrosis Basic Defect. Int J Mol Sci 2021;22:6193. [PMID: 34201249 DOI: 10.3390/ijms22126193] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
28 Guimbellot J, Sharma J, Rowe SM. Toward inclusive therapy with CFTR modulators: Progress and challenges. Pediatr Pulmonol 2017;52:S4-S14. [PMID: 28881097 DOI: 10.1002/ppul.23773] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
29 Coverstone AM, Ferkol TW. Early Diagnosis and Intervention in Cystic Fibrosis: Imagining the Unimaginable. Front Pediatr 2020;8:608821. [PMID: 33505947 DOI: 10.3389/fped.2020.608821] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Bass R, Brownell JN, Stallings VA. The Impact of Highly Effective CFTR Modulators on Growth and Nutrition Status. Nutrients 2021;13:2907. [PMID: 34578785 DOI: 10.3390/nu13092907] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Gentzsch M, Mall MA. Ion Channel Modulators in Cystic Fibrosis. Chest. 2018;154:383-393. [PMID: 29750923 DOI: 10.1016/j.chest.2018.04.036] [Cited by in Crossref: 65] [Cited by in F6Publishing: 52] [Article Influence: 16.3] [Reference Citation Analysis]
32 Duckers J, Lesher B, Thorat T, Lucas E, McGarry LJ, Chandarana K, De Iorio F. Real-World Outcomes of Ivacaftor Treatment in People with Cystic Fibrosis: A Systematic Review. J Clin Med 2021;10:1527. [PMID: 33917386 DOI: 10.3390/jcm10071527] [Reference Citation Analysis]
33 Aalbers B, de Winter-de Groot K, Arets H, Hofland R, de Kiviet A, van Oirschot-van de Ven M, Kruijswijk M, Schotman S, Michel S, van der Ent C, Heijerman H. Clinical effect of lumacaftor/ivacaftor in F508del homozygous CF patients with FEV1 ≥ 90% predicted at baseline. Journal of Cystic Fibrosis 2020;19:654-8. [DOI: 10.1016/j.jcf.2019.12.015] [Cited by in Crossref: 5] [Article Influence: 2.5] [Reference Citation Analysis]
34 Sergeev V, Chou FY, Lam GY, Hamilton CM, Wilcox PG, Quon BS. The Extrapulmonary Effects of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Cystic Fibrosis. Ann Am Thorac Soc 2020;17:147-54. [PMID: 31661636 DOI: 10.1513/AnnalsATS.201909-671CME] [Cited by in Crossref: 24] [Cited by in F6Publishing: 7] [Article Influence: 24.0] [Reference Citation Analysis]
35 Staufer K. Current Treatment Options for Cystic Fibrosis-Related Liver Disease. Int J Mol Sci 2020;21:E8586. [PMID: 33202578 DOI: 10.3390/ijms21228586] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
36 Shei RJ, Mackintosh KA, Peabody Lever JE, McNarry MA, Krick S. Exercise Physiology Across the Lifespan in Cystic Fibrosis. Front Physiol 2019;10:1382. [PMID: 31780953 DOI: 10.3389/fphys.2019.01382] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
37 Lopes-Pacheco M. CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine. Front Pharmacol 2019;10:1662. [PMID: 32153386 DOI: 10.3389/fphar.2019.01662] [Cited by in Crossref: 63] [Cited by in F6Publishing: 56] [Article Influence: 31.5] [Reference Citation Analysis]
38 Harutyunyan M, Huang Y, Mun KS, Yang F, Arora K, Naren AP. Personalized medicine in CF: from modulator development to therapy for cystic fibrosis patients with rare CFTR mutations. Am J Physiol Lung Cell Mol Physiol 2018;314:L529-43. [PMID: 29351449 DOI: 10.1152/ajplung.00465.2017] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
39 Bratcher PE, Yadav S, Shaughnessy CA, Thornell IM, Zeitlin PL. Effect of apical chloride concentration on the measurement of responses to CFTR modulation in airway epithelia cultured from nasal brushings. Physiol Rep 2020;8:e14603. [PMID: 33038073 DOI: 10.14814/phy2.14603] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
40 Bui S, Macey J, Fayon M, Bihouée T, Burgel P, Colomb V, Corvol H, Durieu I, Hubert D, Marguet C, Mas E, Munck A, Murris-espin M, Reix P, Sermet-gaudelus I. Nouvelles thérapeutiques ciblant le canal chlorure dans la mucoviscidose. Archives de Pédiatrie 2016;23:12S47-53. [DOI: 10.1016/s0929-693x(17)30062-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
41 Petersen MC, Begnel L, Wallendorf M, Litvin M. Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis. J Cyst Fibros 2021:S1569-1993(21)02153-6. [PMID: 34862121 DOI: 10.1016/j.jcf.2021.11.012] [Reference Citation Analysis]
42 Sun X, Yi Y, Yan Z, Rosen BH, Liang B, Winter MC, Evans TIA, Rotti PG, Yang Y, Gray JS, Park SY, Zhou W, Zhang Y, Moll SR, Woody L, Tran DM, Jiang L, Vonk AM, Beekman JM, Negulescu P, Van Goor F, Fiorino DF, Gibson-Corley KN, Engelhardt JF. In utero and postnatal VX-770 administration rescues multiorgan disease in a ferret model of cystic fibrosis. Sci Transl Med 2019;11:eaau7531. [PMID: 30918114 DOI: 10.1126/scitranslmed.aau7531] [Cited by in Crossref: 54] [Cited by in F6Publishing: 40] [Article Influence: 27.0] [Reference Citation Analysis]
43 Clunes LA, McMillan-Castanares N, Mehta N, Mesadieu A, Rodriguez J, Maj M, Clunes MT. Epithelial vectorial ion transport in cystic fibrosis: Dysfunction, measurement, and pharmacotherapy to target the primary deficit. SAGE Open Med 2020;8:2050312120933807. [PMID: 32637102 DOI: 10.1177/2050312120933807] [Reference Citation Analysis]
44 Balfour-Lynn IM. Clinical papers of the year 2018 - Cystic fibrosis. Paediatr Respir Rev 2020;33:58-61. [PMID: 31053358 DOI: 10.1016/j.prrv.2019.03.008] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
45 Schmidt BZ, Haaf JB, Leal T, Noel S. Cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis: current perspectives. Clin Pharmacol. 2016;8:127-140. [PMID: 27703398 DOI: 10.2147/cpaa.s100759] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
46 Skilton M, Krishan A, Patel S, Sinha IP, Southern KW. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis. Cochrane Database Syst Rev 2019;1:CD009841. [PMID: 30616300 DOI: 10.1002/14651858.CD009841.pub3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
47 Zemanick ET, Ong T, Daines CL, Dellon EP, Muhlebach MS, Esther CR Jr. Highlights from the 2015 North American Cystic Fibrosis Conference. Pediatr Pulmonol 2016;51:650-7. [PMID: 27074261 DOI: 10.1002/ppul.23441] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
48 Caudri D, Turkovic L, de Klerk NH, Rosenow T, Murray CP, Steyerberg EW, Ranganathan SC, Sly P, Stick SM, Breuer O; AREST CF Study Group. A screening tool to identify risk for bronchiectasis progression in children with cystic fibrosis. Pediatr Pulmonol 2022;57:122-31. [PMID: 34596357 DOI: 10.1002/ppul.25712] [Reference Citation Analysis]
49 Laselva O, Guerra L, Castellani S, Favia M, Di Gioia S, Conese M. Small-molecule drugs for cystic fibrosis: Where are we now? Pulm Pharmacol Ther 2021;:102098. [PMID: 34793977 DOI: 10.1016/j.pupt.2021.102098] [Reference Citation Analysis]
50 Fayon M, Ladipo Y, Galodé F, Debelleix S, Reix P. Atteinte respiratoire précoce dans la mucoviscidose. Archives de Pédiatrie 2016;23:12S9-12S14. [DOI: 10.1016/s0929-693x(17)30057-x] [Reference Citation Analysis]
51 Lopes-Pacheco M. CFTR Modulators: Shedding Light on Precision Medicine for Cystic Fibrosis. Front Pharmacol 2016;7:275. [PMID: 27656143 DOI: 10.3389/fphar.2016.00275] [Cited by in Crossref: 71] [Cited by in F6Publishing: 59] [Article Influence: 11.8] [Reference Citation Analysis]
52 Dobra R, Edmondson C, Hughes D, Martin I, Davies JC. Potentiators and Correctors in Paediatric Cystic Fibrosis Patients: A Narrative Review. Paediatr Drugs 2018;20:555-66. [PMID: 30328089 DOI: 10.1007/s40272-018-0315-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
53 Gabel ME, Fox CK, Grimes RA, Lowman JD, McDonald CM, Stallings VA, Michel SH. Overweight and cystic fibrosis: An unexpected challenge. Pediatr Pulmonol 2021. [PMID: 34738328 DOI: 10.1002/ppul.25748] [Reference Citation Analysis]
54 Kramer EL, Clancy JP. CFTR Modulator Therapies in Pediatric Cystic Fibrosis: Focus on Ivacaftor. Expert Opin Orphan Drugs 2016;4:1033-42. [PMID: 28042521 DOI: 10.1080/21678707.2016.1226800] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
55 Pilewski JM, De Boeck K, Nick JA, Tian S, DeSouza C, Higgins M, Moss RB. Long-Term Ivacaftor in People Aged 6 Years and Older with Cystic Fibrosis with Ivacaftor-Responsive Mutations. Pulm Ther 2020;6:303-13. [PMID: 32965659 DOI: 10.1007/s41030-020-00129-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
56 Slae M, Wilschanski M. Cystic fibrosis and the gut. Frontline Gastroenterol 2021;12:622-8. [PMID: 34917319 DOI: 10.1136/flgastro-2020-101610] [Reference Citation Analysis]
57 Corvol H, Mésinèle J, Douksieh IH, Strug LJ, Boëlle PY, Guillot L. SLC26A9 Gene Is Associated With Lung Function Response to Ivacaftor in Patients With Cystic Fibrosis. Front Pharmacol 2018;9:828. [PMID: 30140228 DOI: 10.3389/fphar.2018.00828] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
58 Mayer-Hamblett N, van Koningsbruggen-Rietschel S, Nichols DP, VanDevanter DR, Davies JC, Lee T, Durmowicz AG, Ratjen F, Konstan MW, Pearson K, Bell SC, Clancy JP, Taylor-Cousar JL, De Boeck K, Donaldson SH, Downey DG, Flume PA, Drevinek P, Goss CH, Fajac I, Magaret AS, Quon BS, Singleton SM, VanDalfsen JM, Retsch-Bogart GZ. Building global development strategies for cf therapeutics during a transitional cftr modulator era. J Cyst Fibros 2020;19:677-87. [PMID: 32522463 DOI: 10.1016/j.jcf.2020.05.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
59 Paranjapye A, Ruffin M, Harris A, Corvol H. Genetic variation in CFTR and modifier loci may modulate cystic fibrosis disease severity. J Cyst Fibros 2020;19 Suppl 1:S10-4. [PMID: 31734115 DOI: 10.1016/j.jcf.2019.11.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
60 Ratjen F, Klingel M, Black P, Powers MR, Grasemann H, Solomon M, Sagel SD, Donaldson SH, Rowe SM, Rosenfeld M. Changes in Lung Clearance Index in Preschool-aged Patients with Cystic Fibrosis Treated with Ivacaftor (GOAL): A Clinical Trial. Am J Respir Crit Care Med 2018;198:526-8. [PMID: 29614238 DOI: 10.1164/rccm.201802-0243LE] [Cited by in Crossref: 20] [Cited by in F6Publishing: 6] [Article Influence: 6.7] [Reference Citation Analysis]
61 Murphy P, Kabir MH, Srivastava T, Mason ME, Dewi CU, Lim S, Yang A, Djordjevic D, Killingsworth MC, Ho JWK, Harman DG, O'Connor MD. Light-focusing human micro-lenses generated from pluripotent stem cells model lens development and drug-induced cataract in vitro. Development. 2018;145. [PMID: 29217756 DOI: 10.1242/dev.155838] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
62 Zemanick ET, Daines CL, Dellon EP, Esther CR Jr, Kinghorn B, Ong T, Muhlebach MS. Highlights from the 2016 North American Cystic Fibrosis Conference. Pediatr Pulmonol 2017;52:1103-10. [PMID: 28696526 DOI: 10.1002/ppul.23707] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
63 Johns JD, Rowe SM. The effect of CFTR modulators on a cystic fibrosis patient presenting with recurrent pancreatitis in the absence of respiratory symptoms: a case report. BMC Gastroenterol 2019;19:123. [PMID: 31296159 DOI: 10.1186/s12876-019-1044-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
64 Proesmans M. Best practices in the treatment of early cystic fibrosis lung disease. Ther Adv Respir Dis 2017;11:97-104. [PMID: 27913761 DOI: 10.1177/1753465816680573] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
65 Girón Moreno RM, García-Clemente M, Diab-Cáceres L, Martínez-Vergara A, Martínez-García MÁ, Gómez-Punter RM. Treatment of Pulmonary Disease of Cystic Fibrosis: A Comprehensive Review. Antibiotics (Basel) 2021;10:486. [PMID: 33922413 DOI: 10.3390/antibiotics10050486] [Reference Citation Analysis]
66 Ramos KJ, Pilewski JM, Taylor-Cousar JL. Challenges in the use of highly effective modulator treatment for cystic fibrosis. J Cyst Fibros 2021;20:381-7. [PMID: 33531206 DOI: 10.1016/j.jcf.2021.01.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
67 Taylor-Cousar JL, Mall MA, Ramsey BW, McKone EF, Tullis E, Marigowda G, McKee CM, Waltz D, Moskowitz SM, Savage J, Xuan F, Rowe SM. Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles. ERJ Open Res 2019;5:00082-2019. [PMID: 31218221 DOI: 10.1183/23120541.00082-2019] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 10.7] [Reference Citation Analysis]
68 van der Meer R, Wilms EB, Heijerman HGM. CFTR Modulators: Does One Dose Fit All? J Pers Med 2021;11:458. [PMID: 34073663 DOI: 10.3390/jpm11060458] [Reference Citation Analysis]
69 Habib AR, Kajbafzadeh M, Desai S, Yang CL, Skolnik K, Quon BS. A Systematic Review of the Clinical Efficacy and Safety of CFTR Modulators in Cystic Fibrosis. Sci Rep 2019;9:7234. [PMID: 31076617 DOI: 10.1038/s41598-019-43652-2] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 11.0] [Reference Citation Analysis]
70 Barry PJ, Taylor-Cousar JL. Triple combination cystic fibrosis transmembrane conductance regulator modulator therapy in the real world - opportunities and challenges. Curr Opin Pulm Med 2021;27:554-66. [PMID: 34420018 DOI: 10.1097/MCP.0000000000000819] [Reference Citation Analysis]
71 Stahl M, Steinke E, Mall MA. Quantification of Phenotypic Variability of Lung Disease in Children with Cystic Fibrosis. Genes (Basel) 2021;12:803. [PMID: 34070354 DOI: 10.3390/genes12060803] [Reference Citation Analysis]